Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope

Journal of Immunology

Volumn 172, Issue 11, 2004, Pages 6658-6665

  Yeung, V Peter ^a   Chang, Judy ^a   Miller, Jeff ^a   Barnett, Christopher ^a   Stickler, Marcia ^a   Harding, Fiona A ^a  

^a GENENCOR INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; EPITOPE; IMMUNOGLOBULIN G1; ISOLEUCINE; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; T LYMPHOCYTE;

EID: 2442661578     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.11.6658     Document Type: Article

References (42)

1. Jenkins, D. E., L. L. Yasukawa, R. Bergen, C. Benike, E. G. Engleman, and A. M. Arvin. 1999. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. J. Immunol. 162:560.
2. + T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J. Virol. 70:4787.
3. Sipsas, N. V., S. A. Kalams, A. Trocha, S. He, W. A. Blattner, B. D. Walker, and R. P. Johnson. 1997. Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J. Clin. Invest. 99:752.
4. + T cell epitope identification: applications to allergy. Clin. Exp. Allergy 33:557.
5. + T-cell peptide epitope determinants, J. Immunol. Methods 281:95.
6. Hesse, M. D., A. Y. Karulin, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann. 2001. A T cell clone's avidity is a function of its activation state. J. Immunol. 167:1353.
7. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 356:607.
8. Tanchot, C., F. A. Lemonnier, B. Perarnau, A. A. Freitas, and B. Rocha. 1997. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276:2057.
9. + memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J. Immunol. 161:5284.
10. Tian, J., S. Gregori, L. Adorini, and D. L. Kaufman. 2001. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J. Immunol. 166:7144.
11. Vanderlugt, C. L., K. L. Neville, K. M. Nikcevich, T. N. Eagar, J. A. Bluestone, and S. D. Miller. 2000. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 164:670.
12. Vanderlugt, C. L., and S. D. Miller. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2:85.
13. Yin, L., M. Yu, A. E. Edling, J. A. Kawczak, P. M. Mathisen, T. Nanavati, J. M. Johnson, and V. K. Tuohy. 2001. Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease. J. Immunol. 167:6105.
14. Karandikar, N. J., T. N. Eagar, C. L. Vanderlugt, J. A. Bluestone, and S. D. Miller. 2000. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109:173.
15. Antonelli, G., F. Bagnato, C. Pozzilli, E. Simeoni, S. Bastianelli, M. Currenti, F. De Pisa, C. Fieschi, C. Gasperini, M. Salvetti, et al. 1998. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J. Interferon Cytokine Res. 18:345.
16. Fernandez, O., C. Mayorga, G. Luque, M. Guerrero, R. Guerrero, L. Leyva, A. Leon, and M. Blanca. 2001. Study of binding and neutralising antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients. J. Neurol. 248:383.
17. Scagnolari, C., F. Bellomi, O. Turriziani, F. Bagnato, V. Tomassini, V. Lavolpe, M. Ruggieri, F. Bruschi, G. Meucci, G. Dicuonzo, et al. 2002. Neutralizing and binding antibodies to IFN-β: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. J. Interferon Cytokine Res. 22:207.
18. PRISMS. 2001. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628.
19. Bertolotto, A., F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L. Lindberg, R. Bottero, et al. 2003. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60:634.
20. Deisenhammer, F., M. Reindl, J. Harvey, T. Gasse, E. Dilitz, and T. Berger. 1999. Bioavailability of interferon β1b in MS patients with and without neutralizing antibodies. Neurology 52:1239.
21. + T-cell epitope in human interferon-β. Genes Immun. 5:1.
22. Russell-Harde, D., M. Knauf, and E. Croze. 1995. The use of Zwittergent 3-14 in the purification of recombinant human interferon-β Ser17 (Betaseron). J. Interferon Cytokine Res. 15:31.
23. Runkel, L., C. deDios, M. Karpusas, M. Betzenhauser, C. Muldowney, M. Zafari, C. D. Benjamin, S. Miller, P. S. Hochman, and A. Whitty. 2000. Systematic mutational mapping of sites on human interferon-β-1a that are important for receptor binding and functional activity. Biochemistry 39:2538.
24. Maeji, N. J., A. M. Bray, and H. M. Geysen. 1990. Multi-pin peptide synthesis strategy for T cell determinant analysis. J. Immunol. Methods 134:23.
25. Liu, Z. R., K. P. Williams, Y. H. Chang, and J. A. Smith. 1991. Single amino acid substitution alters T cell determinant selection during antigen processing of Staphylococcus aureus nuclease. J. Immunol. 146:438.
26. Ma, C., P. E. Whiteley, P. M. Cameron, D. C. Freed, A. Pressey, S. L. Chen, B. Garni-Wagner, C. Fang, D. M. Zaller, L. S. Wicker, et al. 1999. Role of APC in the selection of immunodominant T cell epitopes. J. Immunol. 163:6413.
27. So, T., H. Ito, M. Hirata, T. Ueda, and T. Imoto. 2001. Contribution of conformational stability of hen lysozyme to induction of type 2 T-helper immune responses. Immunology 104:259.
28. Chen, W., J. W. Yewdell, R. L. Levine, and J. R. Bennink. 1999. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J. Exp. Med. 189:1757.
29. Lo-Man, R., J. P. Langeveld, P. Martineau, M. Hofnung, R. H. Meloen, and C. Leclerc. 1998. Immunodominance does not result from peptide competition for MHC class II presentation. J. Immunol. 160:1759.
30. Liu, Z., K. P. Williams, Y. H. Chang, and J. A. Smith. 1993. Immunodominance: a single amino acid substitution within an antigenic site alters intramolecular selection of T cell determinants. J. Immunol. 151:1852.
31. Grewal, I. S., K. D. Moudgil, and E. E. Sercarz. 1995. Hindrance of binding to class II major histocompatibility complex molecules by a single amino acid residue contiguous to a determinant leads to crypticity of the determinant as well as lack of response to the protein antigen. Proc. Natl. Acad. Sci. USA 92:1779.
32. Jang, Y. S., J. A. Mikszta, and B. S. Kim. 1994. T cell epitope recognition involved in the low-responsiveness to a region of hen egg lysozyme (46-61) in C57BL/6 mice. Mol. Immunol. 31:803.
33. Kim, B. S., and Y. S. Jang. 1992. Constraints in antigen processing result in unresponsiveness to a T cell epitope of hen egg lysozyme in C57BL/6 mice. Eur. J. Immunol. 22:775.
34. + T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 198:399.
35. Velazquez, C., R. DiPaolo, and E. R. Unanue. 2001. Quantitation of lysozyme peptides bound to class ii mhc molecules indicates very large differences in levels of presentation. J. Immunol. 166:5488.
36. + T cell response to a model antigen. J. Immunol. 169:1.
37. DiPaolo, R. J., and E. R. Unanue. 2002. Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways. J. Immunol. 169:2832.
38. Gugasyan, R., C. Velazquez, I. Vidavsky, B. M. Deck, K. van der Drift, M. L. Gross, and E. R. Unanue. 2000. Independent selection by I-Ak molecules of two epitopes found in tandem in an extended polypeptide antigen. J. Immunol. 165:3206.
39. Manoury, B., E. W. Hewitt, N. Morrice, P. M. Dando, A. J. Barrett, and C. Watts. 1998. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396:695.
40. Schneider, S. C., J. Ohmen, L. Fosdick, B. Gladstone, J. Guo, A. Ametani, E. E. Sercarz, and H. Deng. 2000. Cutting edge: introduction of an endopeptidase cleavage motif into a determinant flanking region of hen egg lysozyme results in enhanced T cell determinant display. J. Immunol. 165:20.
41. Nanda, N. K., and A. J. Sant. 2000. DM determines the cryptic and immunodominant fate of T cell epitopes. J. Exp. Med. 192:781.
42. Hall, F. C., J. D. Rabinowitz, R. Busch, K. C. Visconti, M. Belmares, N. S. Patil, A. P. Cope, S. Patel, H. M. McConnell, E. D. Mellins, et al. 2002. Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur. J. Immunol. 32:662.